
Major US volcano predicted to erupt TOMORROW
The most active volcano in the Pacific Northwest could erupt as soon as tomorrow, scientists warn.
The Axial Seamount is a mile-wide underwater volcano that sits 300 miles off the coast of Oregon and more than 4,900 feet below the surface of the Pacific Ocean.
It last erupted in 2015, triggering roughly 8,000 earthquakes, producing 400-foot-thick lava flows and causing the bottom of the ocean to sink nearly eight feet.
Now, researchers with the National Science Foundation's Ocean Observatories Initiative, say there's been another massive uptick in the number of earthquakes under the seamount - signaling a looming eruption.
According to William Wilcock, a professor and marine geophysicist at the University of Washington, there have been hundreds of earthquakes in the last few days and the seafloor has already inflated to the level that it reached before the 2015 eruption.
The swelling means that dangerously hot magma is building up beneath the surface.
'At the moment, there are a couple hundred earthquakes a day, but that's still a lot less than we saw before the previous eruption,' Wilcock explained.
'I would say it was going to erupt sometime later (this year) or early 2026, but it could be tomorrow, because it's completely unpredictable,' the marine geophysicist added.
The region has seen a sharp rise in the number of earthquakes in just the last month, with a major spike in activity recorded on April 13.
Since May 6, the number of daily earthquakes under the seamount has been steadily rising.
If Axial Seamount does blow within the next few days, it won't pose any threat human communities along the West Coast, experts say.
It's too deep and too far from shore for people to even notice when it erupts, and it has no impact on seismic activity on land.
However, the number of underwater quakes is expected to skyrocket during this event, rising from several hundred per day right now to 10,000 earthquakes within a 24-hour period as magma flows out of the seafloor volcano, according to Interesting Engineering.
Mike Poland, a scientist at the Yellowstone Volcano Observatory, expressed excitement about the eruption, highlighting Axial Seamount as one of the world's best-monitored submarine volcanoes.
'This particular volcano is probably the best-monitored submarine volcano in the world,' he told Cowboy State Daily. 'It's fascinating and doesn't really pose a hazard.'
Situated along the Juan de Fuca Ridge, a chain of undersea volcanoes extending between Oregon and Alaska, Axial Seamount is a young shield volcano - a broader volcano with a low profile.
'When Axial Seamount erupts, it'll look a lot like a Hawaiian lava flow eruption,' Poland said.
'It's not an explosive eruption, but calm effusions of lava flowing out of the caldera and across the seafloor.'
Scientists warned last year that Axial Seamount was going to erupt by the end of 2025.
'Because it's had these three eruptions in the last 30 years, that's why we call it the most active volcano in the Pacific Northwest, because most of the ones on land aren't active that frequently, and they spend a lot of their time slumbering, whereas Axial has a pretty active magma supply,' Chadwick told local CBS affiliate KOIN 6 News.
'So, if it's not erupting, it's inflating and getting ready for the next one. And so that's why we're kind of monitoring what's happening to it all the time.'
Eruptions from Axial Seamount were recorded in 1998, 2011, and 2015, and the volcano has undoubtedly erupted numerous times prior to those events, according to Poland.
In November 2024, Oregon State University geophysicist William Chadwick started investigating the volcano when he noticed its surface had swelled to nearly the same height it reached before its last eruption 10 years ago.
The swelling that occurred prior to the 2015 eruption allowed Chadwick and his colleagues to predict that event.
This time, their observations told them that Axial Seamount would erupt before the end of 2025.
'Based on the current trends, and the assumption that Axial will be primed to erupt when it reaches the 2015 inflation threshold, our current eruption forecast window is between now (July 2024) and the end of 2025,' the researchers reported.
They also found that seismic activity at Axial Seamount had increased, with hundreds of earthquakes generated around the volcano per day and earthquake swarms greater than 500 per day.
Frequent, small earthquakes like these can signal that magma locked beneath the ocean floor is creeping closer to the surface.
The team shared their findings at the annual American Geophysical Union conference in December 2024.
Wilcock noted that the first sign that an eruption from this volcano is imminent would be a sharp increase in the number of earthquakes around it - which the area is now experiencing.
'That period lasts about an hour, and then the magma reaches the surface,' Wilcock said in a statement last month.
After that, 'the seismic activity dies down pretty quickly over the next few days, but the eruption will continue slowly for about a month,' he added.
This impending eruption will be a major research opportunity for Wilcock and other scientists, who plan to use a suite of high-tech instruments to monitor the eruption from start to finish.
The University of Washington's College of the Environment hosts one of the largest underwater observatories in the world, comprised of networks of sensors along the seafloor and throughout the ocean waters.
When Axial Seamount finally erupts, Wilcock and his colleagues will use this array to gather data and images of the event as it unfolds.
Even though Axial is not a dangerous undersea volcano, the forecasting capabilities scientists have gained from studying it could help them predict eruptions from those that are.
For example, in January 2022, an extremely powerful eruption of the Hunga underwater volcano in the Tonga archipelago in the southern Pacific Ocean triggered a tsunami that caused an estimated $90 billion in damages.
This massive wave impacted California, Hawaii, and parts of Canada, Chile, Fiji, Japan, New Zealand, Mexico and Peru.
The West Coast won't have to worry about Axial causing an event like that. But its eruption will provide an opportunity for scientists to learn more about how these powerful geological structures work - and now it could come at any time.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Daily Mail
an hour ago
- Daily Mail
The iconic landmarks set to be wiped out by The Big One... as experts raise earthquake threat level
The Hollywood sign and the Golden Gate Bridge are among the iconic landmarks set to be wiped out by a huge earthquake when 'The Big One' hits California, experts warn. The devastating seismic event is guaranteed to happen according to scientists, who are increasingly sure it will occur in the next three decades.


The Guardian
3 hours ago
- The Guardian
Alzheimer's blood test can spot people with early symptoms, study suggests
A new blood test for Alzheimer's disease can accurately detect people with early symptoms, research suggests. Experts from the Mayo Clinic in the US have provided further evidence that blood tests can work to accurately diagnose dementia by examining two proteins in blood plasma. The proteins – amyloid beta 42/40 and p-tau217 – are associated with amyloid plaque buildup, which is a hallmark of Alzheimer's disease. Researchers found the blood test was highly accurate, with 95% sensitivity, which means it was 95% accurate in picking up people with memory problems, with very few cases missed. It was also 82% for specificity, which means it was also highly accurate in ruling out people without dementia. The study was carried out on more than 500 people in an outpatient memory clinic, meaning it is real-world data. The blood test has been approved by the Food and Drug Administration regulator in the US. Dr Gregg Day, who led the study in the journal Alzheimer's and Dementia, said the test was as good as more invasive tests in use. 'Our study found that blood testing affirmed the diagnosis of Alzheimer's disease with 95% sensitivity and 82% specificity,' he said. 'When performed in the outpatient clinical setting, this is similar to the accuracy of cerebrospinal fluid biomarkers of the disease and is much more convenient and cost-effective.' Overall, researchers found that p-tau217 levels were higher in patients with Alzheimer's disease versus those without the disease. Day said the next steps in the research were to evaluate blood-based testing in more diverse patient populations and people with early Alzheimer's who showed no cognitive symptoms. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results 'suggest this test is very accurate' and could be used alongside other tests and observations from a trained health professional. 'This study shows how blood tests are making diagnosis of Alzheimer's disease quicker, easier and more accessible than ever before in a real-world setting,' he added. 'While focused on Alzheimer's disease, the test was evaluated in people with other types of dementias too, showing that it may help with differentiate causes of cognitive decline, though more research in diverse groups of individuals and in community-based setting is still needed. 'Currently diagnosis options in the UK are often slow, expensive and can be invasive, meaning thousands miss out on the benefits one can bring. 'It's great to see blood tests like this approved for clinical use in the US. We hope to see the same in the NHS, which is why we're part of the Blood Biomarker Challenge.' The Blood Biomarker Challenge is a multimillion-pound research programme supported by the Alzheimer's Society, Alzheimer's Research UK and the National Institute for Health and Care Research. Its goal is to bring blood tests for dementia diagnosis to the National Health Service by 2029. Oakley said: 'Blood tests will be critical to accelerate diagnosis and give more people access to the care, support and treatments they desperately need faster than ever before. 'We must see long-term investment in the tools and workforce needed to ensure everyone living with dementia can get an early an accurate diagnosis, which is even more important with disease-modifying treatments on the horizon.' Dr Julia Dudley, head of research at Alzheimer's Research UK, said: 'We urgently need to improve how we diagnose dementia and it's great to see international research working towards this goal. 'Blood tests in this study look at p-tau217 and amyloid beta 42/40 and showed the tests offered high accuracy in confirming Alzheimer's disease. 'This study adds to the growing evidence that blood tests can detect the diseases that cause dementia in people with early memory and thinking problems. 'An important point to consider is that people taking part in research don't always reflect the full diversity of those affected by dementia, who might have additional conditions or other characteristics. 'That is why work is needed to understand whether these blood tests work in a real-world setting. 'In the UK, studies like the Blood Biomarker Challenge are helping to build this evidence. The study is testing blood tests, including p-tau217, in thousands of people from sites across the UK. 'This work will be a crucial part of making diagnosis easier and faster, which will bring us closer to a cure.'


Sky News
6 hours ago
- Sky News
Blood test for Alzheimer's disease is highly accurate, researchers say
Researchers say a new blood test for Alzheimer's disease has been shown to be highly accurate in detecting people with early symptoms. Scientists looked for two proteins - amyloid beta 42/40 and p-tau217 - and found the test was 95% accurate in identifying patients with existing cognitive impairment linked to the condition. The US study involved 509 patients in an outpatient memory clinic in Florida and was published in the medical journal Alzheimer's and Dementia. The test, which has already been approved by the US regulator, was also 82% accurate for specificity, which means it could rule out people without dementia. Dr Gregg Day, who led the study, said the test was as good as existing, but more invasive, tests. He said the next step was to extend the test to a wider range of patients, including those with early Alzheimer's who do not have any cognitive symptoms. Scientists say the two proteins, which they have identified in blood plasma, are associated with the buildup of amyloid plaques. Amyloid protein can be found in our brains, but in Alzheimer's disease, amyloid sticks together and forms abnormal deposits, which are thought to be toxic to brain cells. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results "suggest this test is very accurate". "Blood tests will be critical to accelerate diagnosis and give more people access to the care, support and treatments they desperately need faster than ever before," he added. In the UK, the Blood Biomarker Challenge is a multi-million-pound research programme supported by the Alzheimer's Society, Alzheimer's Research UK and the National Institute for Health and Care Research. 1:09 Its goal is to bring blood tests for dementia diagnosis to the NHS by 2029. Dr Julia Dudley, head of research at Alzheimer's Research UK, said: "We urgently need to improve how we diagnose dementia and it's great to see international research working towards this goal." She said the studies like the Blood Biomarker Challenge are a "crucial part of making diagnosis easier and faster, which will bring us closer to a cure". "The study is testing blood tests, including p-tau217, in thousands of people from sites across the UK," she added.